PT2682397T
(pt)
*
|
2000-07-21 |
2017-05-31 |
Gilead Sciences Inc |
Pró-fármacos de análogos de nucleótido fosfonato e métodos para selecionar e produzir os mesmos
|
US20050033051A1
(en)
*
|
2001-11-14 |
2005-02-10 |
Babu Yarlagadda S |
Nucleosides preparation thereof and use as inhibitors of rna viral polymerases
|
US7388002B2
(en)
*
|
2001-11-14 |
2008-06-17 |
Biocryst Pharmaceuticals, Inc. |
Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
|
US20050239054A1
(en)
*
|
2002-04-26 |
2005-10-27 |
Arimilli Murty N |
Method and compositions for identifying anti-HIV therapeutic compounds
|
WO2003091264A2
(en)
|
2002-04-26 |
2003-11-06 |
Gilead Sciences, Inc. |
Non nucleoside reverse transcriptase inhibitors
|
EP1532157A4
(en)
|
2002-05-13 |
2009-02-25 |
Metabasis Therapeutics Inc |
NEW PRODRUGS FROM PMEA TO PHOSPHONIC ACID BASE AND ITS ANALOG
|
MXPA05007016A
(es)
|
2003-01-14 |
2005-09-12 |
Gilead Sciences Inc |
Composiciones y metodos para terapia antiviral de combinacion.
|
US7427636B2
(en)
|
2003-04-25 |
2008-09-23 |
Gilead Sciences, Inc. |
Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
|
US7470724B2
(en)
|
2003-04-25 |
2008-12-30 |
Gilead Sciences, Inc. |
Phosphonate compounds having immuno-modulatory activity
|
CN101410120A
(zh)
*
|
2003-04-25 |
2009-04-15 |
吉里德科学公司 |
抗炎的膦酸酯化合物
|
US7432261B2
(en)
*
|
2003-04-25 |
2008-10-07 |
Gilead Sciences, Inc. |
Anti-inflammatory phosphonate compounds
|
US20050261237A1
(en)
*
|
2003-04-25 |
2005-11-24 |
Boojamra Constantine G |
Nucleoside phosphonate analogs
|
WO2004096286A2
(en)
*
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Antiviral phosphonate analogs
|
US7452901B2
(en)
*
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
US20090247488A1
(en)
*
|
2003-04-25 |
2009-10-01 |
Carina Cannizzaro |
Anti-inflammatory phosphonate compounds
|
US7407965B2
(en)
*
|
2003-04-25 |
2008-08-05 |
Gilead Sciences, Inc. |
Phosphonate analogs for treating metabolic diseases
|
EA200501676A1
(ru)
*
|
2003-04-25 |
2006-04-28 |
Джилид Сайэнс, Инк. |
Фосфонатсодержащие ингибиторы киназы (варианты), способ их получения, фармацевтическая композиция, лекарственная форма на их основе и способ ингибирования киназы у млекопитающего (варианты)
|
WO2005002626A2
(en)
*
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
WO2004096285A2
(en)
*
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Anti-infective phosphonate conjugates
|
US7427624B2
(en)
|
2003-10-24 |
2008-09-23 |
Gilead Sciences, Inc. |
Purine nucleoside phosphorylase inhibitory phosphonate compounds
|
JP2007508844A
(ja)
*
|
2003-10-24 |
2007-04-12 |
ギリアード サイエンシーズ, インコーポレイテッド |
治療用化合物の同定のための方法および組成物
|
WO2005044308A1
(en)
*
|
2003-10-24 |
2005-05-19 |
Gilead Sciences, Inc. |
Phosphonate analogs of antimetabolites
|
BRPI0418031A
(pt)
*
|
2003-12-22 |
2007-04-17 |
Gilead Sciences Inc |
inibidores de quinase fosfonato-substituìdos
|
JP2007515495A
(ja)
*
|
2003-12-22 |
2007-06-14 |
ギリアード サイエンシーズ, インコーポレイテッド |
4’−置換カルボビル誘導体およびアバカビル誘導体ならびにhivおよびhcv抗ウイルス活性を有する関連化合物
|
US20050153990A1
(en)
*
|
2003-12-22 |
2005-07-14 |
Watkins William J. |
Phosphonate substituted kinase inhibitors
|
RS52433B
(en)
*
|
2003-12-30 |
2013-02-28 |
Gilead Sciences Inc. |
NUCLEOSIDE PHOSPHONATES AND THEIR ANALYSIS FOR THE TREATMENT OF HPV INFECTIONS
|
ES2334149T3
(es)
*
|
2004-01-21 |
2010-03-05 |
Gilead Sciences, Inc. |
Uso de adefovir o tenofovir para inhibir virus de tipo vtmr implicados en el cancer de mama y en la cirrosis biliar primaria.
|
US8411105B1
(en)
|
2004-05-14 |
2013-04-02 |
Nvidia Corporation |
Method and system for computing pixel parameters
|
US7079156B1
(en)
|
2004-05-14 |
2006-07-18 |
Nvidia Corporation |
Method and system for implementing multiple high precision and low precision interpolators for a graphics pipeline
|
US8432394B1
(en)
|
2004-05-14 |
2013-04-30 |
Nvidia Corporation |
Method and system for implementing clamped z value interpolation in a raster stage of a graphics pipeline
|
US8416242B1
(en)
|
2004-05-14 |
2013-04-09 |
Nvidia Corporation |
Method and system for interpolating level-of-detail in graphics processors
|
US7582758B2
(en)
|
2004-06-08 |
2009-09-01 |
Metabasis Therapeutics, Inc. |
Lewis acid mediated synthesis of cyclic esters
|
HUE043207T2
(hu)
*
|
2004-07-27 |
2019-08-28 |
Gilead Sciences Inc |
HIV-gátló vegyületek foszfonát analógjai
|
WO2006110655A2
(en)
|
2005-04-08 |
2006-10-19 |
Chimerix, Inc. |
Compounds, compositions and methods for the treatment of poxvirus infections
|
JP2008538354A
(ja)
*
|
2005-04-08 |
2008-10-23 |
キメリクス,インコーポレイテッド |
ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法
|
CN100359315C
(zh)
*
|
2005-05-26 |
2008-01-02 |
林维宣 |
兽药残留能力验证样品及制备方法
|
TWI375560B
(en)
|
2005-06-13 |
2012-11-01 |
Gilead Sciences Inc |
Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
|
TWI471145B
(zh)
|
2005-06-13 |
2015-02-01 |
Bristol Myers Squibb & Gilead Sciences Llc |
單一式藥學劑量型
|
US8076303B2
(en)
|
2005-12-13 |
2011-12-13 |
Spring Bank Pharmaceuticals, Inc. |
Nucleotide and oligonucleotide prodrugs
|
CN100396689C
(zh)
*
|
2006-03-07 |
2008-06-25 |
中国医学科学院医药生物技术研究所 |
一组具有抑制hiv-1/hbv病毒复制活性的替诺福韦单酯化合物
|
EP2020996B1
(en)
|
2006-05-16 |
2011-11-23 |
Gilead Sciences, Inc. |
Method and compositions for treating hematological malignancies
|
EP2046792B1
(en)
|
2006-07-12 |
2015-02-25 |
Mylan Laboratories Limited |
Process for the preparation of tenofovir
|
US20080261913A1
(en)
*
|
2006-12-28 |
2008-10-23 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of liver disorders
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
US8105489B2
(en)
*
|
2007-06-26 |
2012-01-31 |
The University Of Wyoming Research Corporation |
Treatment and prevention systems for acid mine drainage and halogenated contaminants
|
US8441497B1
(en)
*
|
2007-08-07 |
2013-05-14 |
Nvidia Corporation |
Interpolation of vertex attributes in a graphics processor
|
WO2009094190A2
(en)
*
|
2008-01-25 |
2009-07-30 |
Chimerix, Inc. |
Methods of treating viral infections
|
TWI444384B
(zh)
|
2008-02-20 |
2014-07-11 |
Gilead Sciences Inc |
核苷酸類似物及其在治療惡性腫瘤上的用途
|
JP5757860B2
(ja)
|
2008-04-25 |
2015-08-05 |
シプラ・リミテッド |
結晶形態のテノホビルジソプロキシル及びその製造方法
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
EP2476690A1
(en)
*
|
2008-07-02 |
2012-07-18 |
IDENIX Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
CA2729769C
(en)
|
2008-07-08 |
2017-09-05 |
Gilead Sciences, Inc. |
Salts of hiv inhibitor compounds
|
CL2009002206A1
(es)
|
2008-12-23 |
2011-08-26 |
Gilead Pharmasset Llc |
Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
|
JP5713919B2
(ja)
|
2008-12-23 |
2015-05-07 |
ギリアド ファーマセット エルエルシー |
ヌクレオシドホスホラミデート
|
PA8855701A1
(es)
|
2008-12-23 |
2010-07-27 |
|
Análogos de nucleósidos
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TWI598358B
(zh)
|
2009-05-20 |
2017-09-11 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8614200B2
(en)
|
2009-07-21 |
2013-12-24 |
Chimerix, Inc. |
Compounds, compositions and methods for treating ocular conditions
|
RS52954B
(en)
|
2009-09-21 |
2014-02-28 |
Gilead Sciences Inc. |
PROCEDURES AND INTERMEDIATES FOR THE PRODUCTION OF 1'-CYANOCARBANUCLEOSIDE ANALOGS
|
PL2534150T3
(pl)
|
2010-02-12 |
2017-09-29 |
Chimerix, Inc. |
Sposoby leczenia infekcji wirusowej
|
TW201139457A
(en)
|
2010-03-31 |
2011-11-16 |
Pharmasset Inc |
Stereoselective synthesis of phosphorus containing actives
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
BR112012024661A2
(pt)
|
2010-04-01 |
2015-09-15 |
Centre Nat Rech Scient |
composto, composição farmacêutica e método de tratamento de um hospedeiro infectado com vírus de hepatite c
|
CA2797601A1
(en)
|
2010-04-26 |
2011-11-10 |
Chimerix, Inc. |
Methods of treating retroviral infections and related dosage regimes
|
US9090642B2
(en)
*
|
2010-07-19 |
2015-07-28 |
Gilead Sciences, Inc. |
Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
|
WO2012012776A1
(en)
|
2010-07-22 |
2012-01-26 |
Gilead Sciences, Inc. |
Methods and compounds for treating paramyxoviridae virus infections
|
EP3042910B1
(en)
|
2010-11-30 |
2019-01-09 |
Gilead Pharmasset LLC |
2'-spiro-nucleosides for use in the therapy of hepatitis c
|
BR112013014485B1
(pt)
|
2010-12-10 |
2021-03-30 |
Sigmapharm Laboratories, Llc |
Composições farmacêuticas compreendendo pró-fármacos análogos de nucleotídeos de fosfonato ativos por via oral e sistema de embalagem de recipiente/fechamento contendo as ditas composições
|
ZA201103820B
(en)
|
2010-12-13 |
2012-01-25 |
Laurus Labs Private Ltd |
Process for the preparation of tenofovir
|
WO2012154321A1
(en)
|
2011-03-31 |
2012-11-15 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
WO2012154698A2
(en)
*
|
2011-05-06 |
2012-11-15 |
Mckenna Charles E |
Method to improve antiviral activity of nucleotide analogue drugs
|
PT3199537T
(pt)
|
2011-05-19 |
2019-01-17 |
Gilead Sciences Inc |
Processos e intermediários para preparar agentes anti-hiv
|
AU2014271320B2
(en)
*
|
2011-08-16 |
2017-02-23 |
Gilead Sciences, Inc. |
Tenofovir alafenamide hemifumarate
|
ME02612B
(me)
|
2011-08-16 |
2017-06-20 |
Gilead Sciences Inc |
Tenofovir alafenamid hemifumarat
|
PE20141056A1
(es)
|
2011-09-16 |
2014-09-05 |
Gilead Pharmasset Llc |
Metodos para el tratamiento de vhc
|
AU2016228317B2
(en)
*
|
2011-10-07 |
2018-07-19 |
Gilead Sciences, Inc. |
Methods for preparing anti-viral nucleotide analogs
|
UY34361A
(es)
*
|
2011-10-07 |
2013-05-31 |
Gilead Sciences Inc |
Métodos para preparar análogos nucleotídicos anti virales.
|
AU2014215976B2
(en)
*
|
2011-10-07 |
2016-06-30 |
Gilead Sciences, Inc. |
Methods for preparing anti-viral nucleotide analogs
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
ES2874774T3
(es)
|
2011-12-22 |
2021-11-05 |
Geron Corp |
Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros
|
BR112014018918A8
(pt)
|
2012-02-03 |
2017-07-11 |
Gilead Sciences Inc |
Terapia de combinação compreendendo hemifumarato de tenofovir alafenamida e cobicistato para uso no tratamento de infecções virais
|
AU2012327170A1
(en)
|
2012-02-03 |
2013-08-22 |
Gilead Sciences, Inc. |
Therapeutic compounds
|
CN107312039B
(zh)
*
|
2012-08-30 |
2019-06-25 |
江苏豪森药业集团有限公司 |
一种替诺福韦前药的制备方法
|
GB201215696D0
(en)
*
|
2012-09-03 |
2012-10-17 |
Ithemba Pharmaceuticals Pty Ltd |
A process for the preparation of (R)-9-[2-(Phosphonometh-Oxy)propyl]adenine (PMPA)
|
CA2889903C
(en)
|
2012-10-29 |
2021-03-09 |
Manjinder Singh Phull |
Antiviral phosphonate analogues and process for preparation thereof
|
CN102899327B
(zh)
*
|
2012-11-06 |
2014-06-11 |
清华大学深圳研究生院 |
一种抗病毒的小核酸及其温度敏感型凝胶制剂与应用
|
CN104918939B
(zh)
*
|
2012-11-16 |
2018-08-28 |
默沙东公司 |
人磷脂酰肌醇3-激酶δ的嘌呤抑制剂
|
CN103848869B
(zh)
*
|
2012-12-04 |
2016-12-21 |
上海医药工业研究院 |
制备替诺福韦的方法
|
CN103848868B
(zh)
*
|
2012-12-04 |
2017-04-12 |
蚌埠丰原涂山制药有限公司 |
制备替诺福韦的方法
|
EP3650013A1
(en)
|
2013-01-31 |
2020-05-13 |
Gilead Pharmasset LLC |
Combination formulation of two antiviral compounds
|
CN104072539B
(zh)
*
|
2013-03-25 |
2017-03-29 |
安徽贝克联合制药有限公司 |
替诺福韦双(4‑乙酰氨基苯酚氧基)酯及其制备方法和其应用
|
CN104181221B
(zh)
*
|
2013-05-21 |
2017-02-01 |
成都先导药物开发有限公司 |
一种药物靶标捕获方法
|
IN2013MU01967A
(enEXAMPLES)
|
2013-06-07 |
2015-06-12 |
Cipla Ltd |
|
KR102239196B1
(ko)
|
2013-08-27 |
2021-04-12 |
길리애드 파마셋 엘엘씨 |
2종의 항바이러스 화합물의 조합 제제
|
WO2015040640A2
(en)
*
|
2013-09-20 |
2015-03-26 |
Laurus Labs Private Limited |
An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof
|
EP2860185A1
(en)
|
2013-10-09 |
2015-04-15 |
Zentiva, k.s. |
An improved process for the preparation of Tenofovir disoproxil and pharmaceutically acceptable salts thereof
|
WO2015079455A2
(en)
*
|
2013-11-27 |
2015-06-04 |
Laurus Labs Private Limited |
A recycling process for preparing tenofovir alafenamide diastereomers
|
IN2014MU00118A
(enEXAMPLES)
|
2014-01-14 |
2015-08-28 |
Mylan Lab Ltd |
|
TWI660965B
(zh)
|
2014-01-15 |
2019-06-01 |
美商基利科學股份有限公司 |
泰諾福韋之固體形式
|
CN104804042B
(zh)
*
|
2014-01-24 |
2018-01-19 |
齐鲁制药有限公司 |
核苷酸膦酸酯类化合物、其药物组合物、制备方法及用途
|
US9463194B2
(en)
|
2014-02-05 |
2016-10-11 |
Gilead Sciences, Inc. |
Methods of treating patients co-infected with HIV and tuberculosis
|
CA2937548C
(en)
|
2014-02-13 |
2022-10-25 |
Ligand Pharmaceuticals, Inc. |
Prodrug compounds and their uses
|
WO2015127848A1
(zh)
*
|
2014-02-27 |
2015-09-03 |
四川海思科制药有限公司 |
一种取代的氨基磷酸酯类衍生物、其制备方法及其应用
|
CN105001262B
(zh)
*
|
2014-04-18 |
2017-09-01 |
四川海思科制药有限公司 |
芳基取代的磷酰胺类衍生物及其在医学上的应用
|
WO2015161785A1
(zh)
*
|
2014-04-21 |
2015-10-29 |
四川海思科制药有限公司 |
氨基磷酸酯类衍生物制备方法及其中间体和中间体的制备方法
|
CN105085571A
(zh)
*
|
2014-05-20 |
2015-11-25 |
四川海思科制药有限公司 |
替诺福韦艾拉酚胺复合物及其制备方法和用途
|
WO2015197006A1
(zh)
*
|
2014-06-25 |
2015-12-30 |
四川海思科制药有限公司 |
一种取代的氨基酸硫酯类化合物、其组合物及应用
|
JP2017520545A
(ja)
|
2014-07-02 |
2017-07-27 |
リガンド・ファーマシューティカルズ・インコーポレイテッド |
プロドラッグ化合物およびそれらの使用
|
ES2915381T3
(es)
|
2014-09-15 |
2022-06-22 |
Univ California |
Análogos de nucleótidos
|
KR101703258B1
(ko)
|
2014-12-30 |
2017-02-06 |
한미정밀화학주식회사 |
고순도의 (r)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법
|
CN106687467A
(zh)
*
|
2014-09-30 |
2017-05-17 |
韩美精密化学株式会社 |
高纯度(r)‑9‑[2‑(磷酰甲氧基)丙基]腺嘌呤的制备方法
|
KR101703257B1
(ko)
|
2014-09-30 |
2017-02-06 |
한미정밀화학주식회사 |
고순도의 (r)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법
|
EP3203995A4
(en)
|
2014-10-09 |
2019-05-15 |
Board of Regents of the University of Nebraska |
COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS
|
TWI767201B
(zh)
|
2014-10-29 |
2022-06-11 |
美商基利科學股份有限公司 |
絲狀病毒科病毒感染之治療
|
CN105646584B
(zh)
*
|
2014-11-12 |
2018-09-28 |
四川海思科制药有限公司 |
替诺福韦艾拉酚胺富马酸盐晶型及其制备方法和用途
|
CN104558036A
(zh)
*
|
2014-12-11 |
2015-04-29 |
杭州和泽医药科技有限公司 |
一种替诺福韦艾拉酚胺半反丁烯二酸盐晶型及其制备方法
|
US20170348334A1
(en)
|
2015-01-03 |
2017-12-07 |
Mylan Laboratories Limited |
Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof
|
WO2016187160A1
(en)
*
|
2015-05-16 |
2016-11-24 |
Godx, Inc. |
Point of need testing device and methods of use thereof
|
CN106188139B
(zh)
*
|
2015-05-29 |
2020-02-18 |
江苏天士力帝益药业有限公司 |
替诺福韦单苄酯磷酸酰胺前药、其制备方法及应用
|
CZ2015384A3
(cs)
|
2015-06-05 |
2016-12-14 |
Zentiva, K.S. |
Pevné formy Tenofovir alafenamidu
|
HK1252631A1
(zh)
*
|
2015-06-17 |
2019-05-31 |
Gilead Sciences, Inc. |
替諾福韋艾拉酚胺的共晶體,鹽和固體形式
|
SI3316868T1
(sl)
|
2015-06-30 |
2020-04-30 |
Gilead Sciences, Inc. |
Farmacevtske formulacije, ki vsebujejo tenofovir in emtricitabin
|
KR102163611B1
(ko)
|
2015-08-10 |
2020-10-08 |
머크 샤프 앤드 돔 코포레이션 |
항바이러스 베타-아미노산 에스테르 포스포디아미드 화합물
|
TWI620754B
(zh)
*
|
2015-08-26 |
2018-04-11 |
|
Method for preparing amino phosphate derivative and preparation method thereof
|
TWI616452B
(zh)
*
|
2015-08-26 |
2018-03-01 |
|
Preparation method of nucleoside analog and intermediate thereof
|
TWI616453B
(zh)
*
|
2015-08-27 |
2018-03-01 |
|
Substituted amino acid thioester compounds, compositions and uses thereof
|
WO2017037608A1
(en)
*
|
2015-08-28 |
2017-03-09 |
Laurus Labs Private Limited |
Solid forms of tenofovir alafenamide and salts thereof, processes for its preparation and pharmaceutical compositions thereof
|
CN115887465A
(zh)
|
2015-09-16 |
2023-04-04 |
吉利德科学公司 |
治疗沙粒病毒科和冠状病毒科病毒感染的方法
|
WO2017083304A1
(en)
|
2015-11-09 |
2017-05-18 |
Gilead Sciences, Inc. |
Therapeutic compositions for treatment of human immunodeficiency virus
|
CN106800573B
(zh)
*
|
2015-11-25 |
2020-03-10 |
四川海思科制药有限公司 |
一种核苷酸膦酸酯一水合物及其制备方法和在医药上的应用
|
WO2017100108A1
(en)
|
2015-12-10 |
2017-06-15 |
Merck Sharp & Dohme Corp. |
Antiviral phosphodiamide prodrugs of tenofovir
|
CN106866737B
(zh)
*
|
2015-12-11 |
2020-11-20 |
南京圣和药物研发有限公司 |
膦酸衍生物及其应用
|
EP3390413B1
(en)
|
2015-12-15 |
2020-08-19 |
Merck Sharp & Dohme Corp. |
Antiviral oxime phosphoramide compounds
|
WO2017118928A1
(en)
|
2016-01-06 |
2017-07-13 |
Lupin Limited |
Process for the separation of diastereomers of tenofovir alafenamide
|
WO2017134089A1
(en)
|
2016-02-02 |
2017-08-10 |
Sandoz Ag |
Crystalline forms of tenofovir alafenamide monofumarate
|
WO2017133517A1
(zh)
*
|
2016-02-03 |
2017-08-10 |
四川海思科制药有限公司 |
一种磷酰胺衍生物及制备方法和用途
|
WO2017148290A1
(zh)
*
|
2016-03-01 |
2017-09-08 |
深圳市塔吉瑞生物医药有限公司 |
一种取代的腺嘌呤化合物及其药物组合物
|
CN107179355B
(zh)
*
|
2016-03-11 |
2021-08-10 |
广东东阳光药业有限公司 |
一种分离检测替诺福韦艾拉酚胺及其有关物质的方法
|
CZ2016156A3
(cs)
|
2016-03-17 |
2017-09-27 |
Zentiva, K.S. |
Způsob přípravy diastereomerně čistého Tenofoviru Alafenamidu nebo jeho solí
|
CN107226826A
(zh)
*
|
2016-03-25 |
2017-10-03 |
江苏奥赛康药业股份有限公司 |
替诺福韦艾拉酚胺富马酸盐化合物及其药物组合物
|
CN109476689B
(zh)
*
|
2016-06-05 |
2021-09-03 |
上海诚妙医药科技有限公司 |
富马酸替诺福韦艾拉酚胺盐的新晶型、制备方法及其用途
|
CN107698621A
(zh)
*
|
2016-06-20 |
2018-02-16 |
杭州和泽医药科技有限公司 |
一种腺嘌呤衍生物的膦酸酯前药及其在医药上的应用
|
WO2017221189A1
(en)
*
|
2016-06-22 |
2017-12-28 |
Laurus Labs Limited |
An improved process for the preparation of tenofovir alafenamide or pharmaceutically acceptable salts thereof
|
CN106317116A
(zh)
*
|
2016-08-19 |
2017-01-11 |
张红利 |
磷酰胺核苷类化合物及其药学上可接受的盐与应用、药物组合物
|
HK1256904B
(en)
|
2016-08-19 |
2020-07-17 |
Gilead Sciences, Inc. |
Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
|
US10449208B2
(en)
|
2016-08-25 |
2019-10-22 |
Merck Sharp & Dohme Corp. |
Antiviral prodrugs of tenofovir
|
CN106380484A
(zh)
*
|
2016-08-29 |
2017-02-08 |
杭州百诚医药科技股份有限公司 |
一种替诺福韦艾拉酚胺的新晶型及其制备方法
|
WO2018042331A1
(en)
|
2016-08-31 |
2018-03-08 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Combinations and uses and treatments thereof
|
WO2018051250A1
(en)
|
2016-09-14 |
2018-03-22 |
Viiv Healthcare Company |
Combination comprising tenofovir alafenamide, bictegravir and 3tc
|
WO2018080903A1
(en)
|
2016-10-26 |
2018-05-03 |
Merck Sharp & Dohme Corp. |
Antiviral aryl-amide phosphodiamide compounds
|
CN106565785B
(zh)
*
|
2016-11-09 |
2019-11-12 |
周雨恬 |
一种具有抗hbv/hiv活性的核苷氨基磷酸酯类化合物及其盐和用途
|
CN108129514A
(zh)
*
|
2016-12-01 |
2018-06-08 |
北京美倍他药物研究有限公司 |
磷酸/膦酸衍生物的单一异构体及其医药用途
|
TW201829412A
(zh)
|
2016-12-22 |
2018-08-16 |
美商默沙東藥廠 |
抗病毒之替諾福韋(tenofovir)之脂系酯前藥
|
JP2020504734A
(ja)
*
|
2016-12-22 |
2020-02-13 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
抗ウイルス性ベンジル−アミンホスホジアミド化合物
|
WO2018115046A1
(en)
|
2016-12-23 |
2018-06-28 |
Sandoz Ag |
Crystalline solid forms of tenofovir alafenamide
|
TWI868958B
(zh)
|
2017-01-31 |
2025-01-01 |
美商基利科學股份有限公司 |
替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
|
WO2018153977A1
(en)
|
2017-02-24 |
2018-08-30 |
Hexal Ag |
Stable composition of tenofovir alafenamide
|
RU2647576C1
(ru)
*
|
2017-02-28 |
2018-03-16 |
Васильевич Иващенко Александр |
Циклобутил (S)-2-[[[(R)-2-(6-аминопурин-9-ил)-1-метил-этокси]метил-фенокси-фосфорил]амино]-пропаноаты, способ их получения и применения
|
RU2659388C1
(ru)
|
2017-02-28 |
2018-07-02 |
Васильевич Иващенко Александр |
Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
|
CN106866739B
(zh)
*
|
2017-03-10 |
2018-11-02 |
华东师范大学 |
一种(r)-1-(6-氨基-9h-嘌呤-9-基)2-苯酯的制备方法
|
CN116036112A
(zh)
|
2017-03-14 |
2023-05-02 |
吉利德科学公司 |
治疗猫冠状病毒感染的方法
|
US11191763B2
(en)
|
2017-03-20 |
2021-12-07 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
HIV post-exposure prophylaxis
|
CN108794530A
(zh)
*
|
2017-04-26 |
2018-11-13 |
上海医药工业研究院 |
一种替诺福韦丙酚酰胺盐晶型及其制备方法和用途
|
EP4219513A1
(en)
|
2017-05-01 |
2023-08-02 |
Gilead Sciences, Inc. |
Crystalline form of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
|
KR102379965B1
(ko)
*
|
2017-05-19 |
2022-03-29 |
주식회사 종근당 |
테노포비르의 효율적인 제조방법
|
CN107266499B
(zh)
*
|
2017-06-05 |
2019-07-02 |
珠海优润医药科技有限公司 |
一种抗病毒化合物及其制备方法
|
CN111587107B
(zh)
|
2017-06-30 |
2023-03-31 |
希普拉有限公司 |
药物组合物
|
CN111093627B
(zh)
|
2017-07-11 |
2024-03-08 |
吉利德科学公司 |
用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
|
WO2019021319A1
(en)
|
2017-07-27 |
2019-01-31 |
Cipla Limited |
PHARMACEUTICAL COMPOSITIONS
|
PT3661937T
(pt)
|
2017-08-01 |
2021-09-24 |
Gilead Sciences Inc |
Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais
|
AR112412A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas de sal de colina de un inhibidor de la cápside del vih
|
CN107655987B
(zh)
*
|
2017-09-08 |
2020-11-03 |
厦门蔚扬药业有限公司 |
一种替诺福韦艾拉酚胺及其异构体的hplc检测方法
|
CN107522743A
(zh)
*
|
2017-09-30 |
2017-12-29 |
深圳科兴生物工程有限公司 |
一种半富马酸替诺福韦艾拉酚胺工业化连续生产方法
|
WO2019084020A1
(en)
|
2017-10-24 |
2019-05-02 |
Gilead Sciences, Inc. |
METHODS OF TREATING PATIENTS CO-INFECTED BY A VIRUS AND TUBERCULOSIS
|
CN109942633B
(zh)
*
|
2017-12-20 |
2021-08-31 |
上海新礼泰药业有限公司 |
替诺福韦艾拉酚胺中间体的制备方法
|
CN109942632B
(zh)
*
|
2017-12-20 |
2021-08-31 |
上海博志研新药物研究有限公司 |
替诺福韦艾拉酚胺中间体的制备方法
|
WO2019130354A1
(en)
|
2017-12-30 |
2019-07-04 |
Cipla Limited |
Polymorphic forms of (9-[(r)-2-[[(s)-[[(s)-1- (isopropoxycarbonyl)ethyl]amino]phenoxy phosphinyl]methoxy]propyl] adenine and pharmaceutically acceptable salts thereof
|
CN111788196A
(zh)
|
2018-01-09 |
2020-10-16 |
配体药物公司 |
缩醛化合物及其治疗用途
|
JP7181938B2
(ja)
*
|
2018-01-10 |
2022-12-01 |
ヌクオリオン ファーマシューティカルズ インコーポレイテッド |
ホスホロ(ン)アミダートアセタールおよびホスファ(ホナ)ートアルセタール化合物
|
CA3126348A1
(en)
*
|
2018-01-12 |
2020-07-18 |
Board Of Regents Of The University Of Nebraska |
Antiviral prodrugs and formulations thereof
|
PL3752495T3
(pl)
|
2018-02-15 |
2024-01-15 |
Gilead Sciences, Inc. |
Pochodne pirydynowe i ich zastosowanie do leczenia infekcji hiv
|
PL3752496T3
(pl)
|
2018-02-16 |
2023-11-27 |
Gilead Sciences, Inc. |
Sposoby i związki pośrednie do wytwarzania związku terapeutycznego przydatnego w leczeniu infekcji wirusowej retroviridae
|
CN108101943B
(zh)
*
|
2018-02-28 |
2020-11-24 |
顾世海 |
一种替诺福韦前药或可药用盐及其在医药上的应用
|
CA3132832A1
(en)
|
2018-04-09 |
2019-10-17 |
Howard E. Gendelman |
Antiviral prodrugs and formulations thereof
|
KR20230141905A
(ko)
|
2018-07-16 |
2023-10-10 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv의 치료를 위한 캡시드 억제제
|
WO2020018399A1
(en)
|
2018-07-19 |
2020-01-23 |
Merck Sharp & Dohme Corp. |
Phosphinic amide prodrugs of tenofovir
|
AU2019344929B2
(en)
|
2018-09-19 |
2023-03-30 |
Gilead Sciences, Inc. |
Integrase inhibitors for the prevention of HIV
|
KR102714084B1
(ko)
|
2019-03-22 |
2024-10-08 |
길리애드 사이언시즈, 인코포레이티드 |
가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도
|
US12110311B2
(en)
|
2019-07-17 |
2024-10-08 |
Nucorion Pharmaceuticals, Inc. |
Cyclic deoxyribonucleotide compounds
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
WO2021015818A1
(en)
|
2019-07-19 |
2021-01-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Hiv pre-exposure prophylaxis
|
WO2021034804A1
(en)
|
2019-08-19 |
2021-02-25 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
KR20220083673A
(ko)
*
|
2019-08-22 |
2022-06-20 |
에모리 유니버시티 |
뉴클레오사이드 전구약물 및 이와 관련된 용도
|
KR20230013013A
(ko)
*
|
2019-09-20 |
2023-01-26 |
애보트 라피드 다이어그노스틱스 인터내셔널 언리미티드 컴퍼니 |
테노포비르 및 그의 유도체에 대해 지시된 항체
|
CA3157275A1
(en)
|
2019-11-26 |
2021-06-03 |
Elena BEKERMAN |
Capsid inhibitors for the prevention of hiv
|
CA3163424A1
(en)
|
2020-01-27 |
2021-08-05 |
Gilead Sciences, Inc. |
Methods for treating sars cov-2 infections
|
EP4085062A1
(en)
|
2020-02-20 |
2022-11-09 |
Cipla Limited |
Novel salts and/or co-crystals of tenofovir alafenamide
|
CN118994170A
(zh)
|
2020-03-12 |
2024-11-22 |
吉利德科学公司 |
制备1'-氰基核苷的方法
|
JP2023518433A
(ja)
|
2020-03-20 |
2023-05-01 |
ギリアード サイエンシーズ, インコーポレイテッド |
4’-c-置換-2-ハロ-2’-デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
|
WO2021202669A2
(en)
|
2020-04-01 |
2021-10-07 |
Reyoung Corporation |
Nucleoside and nucleotide conjugate compounds and uses thereof
|
KR20220164784A
(ko)
|
2020-04-06 |
2022-12-13 |
길리애드 사이언시즈, 인코포레이티드 |
1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형
|
KR20210125298A
(ko)
|
2020-04-08 |
2021-10-18 |
주식회사 파마코스텍 |
테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법
|
KR20230004716A
(ko)
|
2020-04-21 |
2023-01-06 |
리간드 파마슈티칼스 인코포레이티드 |
뉴클레오티드 프로드러그 화합물
|
TW202203941A
(zh)
|
2020-05-29 |
2022-02-01 |
美商基利科學股份有限公司 |
瑞德西韋之治療方法
|
PH12022553530A1
(en)
|
2020-06-24 |
2024-06-24 |
Gilead Sciences Inc |
1'-cyano nucleoside analogs and uses thereof
|
WO2021262990A1
(en)
|
2020-06-25 |
2021-12-30 |
Gilead Sciences, Inc. |
Capsid inhibitors for the treatment of hiv
|
CN113970612B
(zh)
*
|
2020-07-22 |
2023-08-01 |
北京四环制药有限公司 |
一种高效液相色谱法测定丙酚替诺福韦有关物质的方法
|
CA3190702A1
(en)
|
2020-08-27 |
2022-03-03 |
Elaine Bunyan |
Compounds and methods for treatment of viral infections
|
CN112336695B
(zh)
*
|
2020-09-28 |
2023-01-03 |
华北制药华坤河北生物技术有限公司 |
一种富马酸丙酚替诺福韦片剂及其制备方法和有关物质的检测方法
|
JP7659628B2
(ja)
|
2020-11-11 |
2025-04-09 |
ギリアード サイエンシーズ, インコーポレイテッド |
gp120 CD4結合部位指向性抗体による治療に感受性のHIV患者を特定する方法
|
US11667656B2
(en)
|
2021-01-27 |
2023-06-06 |
Apotex Inc. |
Crystalline forms of Tenofovir alafenamide
|
CN113075307B
(zh)
*
|
2021-03-08 |
2025-03-11 |
瑞阳制药股份有限公司 |
富马酸丙酚替诺福韦异构体的检测方法
|
CN113214322B
(zh)
*
|
2021-04-30 |
2022-10-25 |
山东立新制药有限公司 |
替诺福韦绿色环保的制备方法
|
WO2022251594A1
(en)
*
|
2021-05-27 |
2022-12-01 |
Antios Therapeutics, Inc. |
Pharmacokinetics and dose-related improvments in subjects treated with phosphoramidate clevudine prodrugs
|
IL312718A
(en)
|
2021-12-03 |
2024-07-01 |
Gilead Sciences Inc |
Therapeutic compounds for HIV infection
|
KR20240113832A
(ko)
|
2021-12-03 |
2024-07-23 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv 바이러스 감염 치료용 화합물
|
WO2023102529A1
(en)
|
2021-12-03 |
2023-06-08 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv virus infection
|
CN114369120A
(zh)
*
|
2022-01-28 |
2022-04-19 |
石家庄龙泽制药股份有限公司 |
一种丙酚替诺福韦关键中间体的制备方法
|
CR20240363A
(es)
|
2022-03-02 |
2024-10-25 |
Gilead Sciences Inc |
Compuestos y métodos para el tratamiento de infecciones virales.
|
TWI843506B
(zh)
|
2022-04-06 |
2024-05-21 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
US20240034724A1
(en)
|
2022-07-01 |
2024-02-01 |
Gilead Sciences, Inc. |
Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
|
IL318465A
(en)
|
2022-07-21 |
2025-03-01 |
Antiva Biosciences Inc |
Compositions and dosage forms for the treatment of HPV infection and HPV-induced neoplasia
|
KR20250051732A
(ko)
|
2022-08-26 |
2025-04-17 |
길리애드 사이언시즈, 인코포레이티드 |
광범위 중화 항체를 위한 투여 및 일정 요법
|
EP4598934A1
(en)
|
2022-10-04 |
2025-08-13 |
Gilead Sciences, Inc. |
4'-thionucleoside analogues and their pharmaceutical use
|
WO2024196814A1
(en)
|
2023-03-17 |
2024-09-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods for treatment of age-related macular degeneration
|
TW202444363A
(zh)
|
2023-04-19 |
2024-11-16 |
美商基利科學股份有限公司 |
殼體抑制劑之給藥方案
|
US20250011352A1
(en)
|
2023-05-31 |
2025-01-09 |
Gilead Sciences, Inc. |
Solid forms
|
US20250042926A1
(en)
|
2023-05-31 |
2025-02-06 |
Gilead Sciences, Inc. |
Therapeutic compounds for hiv
|
WO2025029247A1
(en)
|
2023-07-28 |
2025-02-06 |
Gilead Sciences, Inc. |
Weekly regimen of lenacapavir for the treatment and prevention of hiv
|
WO2025042394A1
(en)
|
2023-08-23 |
2025-02-27 |
Gilead Sciences, Inc. |
Dosing regimen of hiv capsid inhibitor
|
WO2025080850A1
(en)
|
2023-10-11 |
2025-04-17 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
US20250120989A1
(en)
|
2023-10-11 |
2025-04-17 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
US20250122219A1
(en)
|
2023-10-11 |
2025-04-17 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
US20250230163A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Solid forms of hiv integrase inhibitors
|
US12357577B1
(en)
|
2024-02-02 |
2025-07-15 |
Gilead Sciences, Inc. |
Pharmaceutical formulations and uses thereof
|
WO2025184452A1
(en)
|
2024-03-01 |
2025-09-04 |
Gilead Sciences, Inc. |
Solid forms of hiv integrase inhibitors
|
WO2025184447A1
(en)
|
2024-03-01 |
2025-09-04 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising hiv integrase inhibitors
|
WO2025184609A1
(en)
|
2024-03-01 |
2025-09-04 |
Gilead Sciences, Inc. |
Antiviral compounds
|
CN118652277A
(zh)
*
|
2024-08-19 |
2024-09-17 |
成都工业学院 |
一种用于治疗癌症疾病的化合物的制备方法
|